Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis

BACKGROUND: Recently, direct oral anticoagulants (DOACs) have been included in guidelines for the treatment of cancer-associated thrombosis (CAT) to be extended to suitable cancer patients. The purpose of this study was to compare the cost-effectiveness of using DOACs and low molecular weight hepari...

Descripción completa

Detalles Bibliográficos
Autores principales: Wumaier, Kaidireyahan, Li, Wenqian, Chen, Naifei, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479897/
https://www.ncbi.nlm.nih.gov/pubmed/34587969
http://dx.doi.org/10.1186/s12959-021-00319-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479897/
https://www.ncbi.nlm.nih.gov/pubmed/34587969
http://dx.doi.org/10.1186/s12959-021-00319-1

Ejemplares similares